Immunomodulating effect of adjuvant interferon inducers in patients receiving combined photocoagulation/ strontium-90 brachytherapy organ-saving treatment foruveal melanoma
DOI:
https://doi.org/10.31288/oftalmolzh201541722Keywords:
uveal melanoma, immunological correction, interferon inducerAbstract
Background: A great deal of evidence has been accumulated over the last decade indicating that a failure of immunologic control mechanisms plays an important role in the tumor initiation and growth. Our experience argues that a systemic approach to the treatment of cancer will allow not only the enhancement of capabilities of the organ-saving treatment, but also the improvement of prognosis for survival time.
Purpose: To investigate the immunomodulating effect of adjuvant interferon inducer, tilorone, in patients receiving the combined photocoagulation/ strontium-90 brachytherapy treatment for uveal melanoma.
Materials and Methods: This prospective study involved 83 uveal melanoma patients of the Filatov institute oncology department. They were divided into two groups comprising 43 patients who received the combined treatmentwith adjuvant tilorone therapy, and 40 patients whose disease was managed by the combined treatment alone, respectively. The immunological status was determined at the baseline, and at 3-, 6-, and 9-month time points of the study.
Results: In both groups, the baseline immunological features were decreased CD8 (suppressor T cells/ cytotoxic T cells) percentage, increased CD4/CD8 ratio, and subnormal CD16 (natural killer cells) percentage, whereas the baseline humoral immunity features were increased IgA levels with respect to healthy controls. When used as an adjuvant to the combined treatment for uveal melanoma, tilorone offers benefit beyond the combined treatment alone with respect to normalization of the immunological status of the patients (including normalization of suppressor T cells/ cytotoxic T cells (CD8) percentage, NK cells (CD16) percentage, and CD4/CD8 ratio). Additionally, normalization of IgA levels is observed.
Conclusion: Tilorone can be integrated into a complex modality approach for uveal melanoma treatment as an immune correction agent with the anti-tumor resistance-enhancing capacity.
References
1. Velychko LM, Vit VV, Malets'kyi AP, Dragomirets'ka OI. [Immune correction with a2binterferon: an essential component of the treatment of patients with uveal melanoma]. Onkologiia. 2001 2(2):64-7. Ukrainian.
2. Vit VV. [Malignant ocular pathology]. Volume 1. Odessa: Astroprint; 2009. 610 p. Russian.
3. Malets'kyi AP. [Efficiency of the organ-saving treatment of patients with uveal melanoma depending on the clinical and morphological characteristics of the tumor and antitumor resistance of the body]. [Dr. Sc. (Med) Thesis Abstract]. Odesa: Filatov Eye Disease and Tissue Therapy Institute;2001. 32 p. Ukrainian.
4. [Amixin: possibility to use and prospects of using in clinical practice]. Collected analytical articles. Odessa, 2001. 36 p. Russian.
5. Ershov FI, Chizhov NP, Tazulakhova EB. [Antiviral agents]. St Petersburg: St Petersburg; 1993. 104 p. Russian.
6. Andronati SA, editor. [Clinical practice experience with amixin therapy]. Recommendations for doctors. Odessa, 2001. 60 p. Russian.
7. Grigorian SS, Ershov FI. [Clinical efficacy of interferon inducers. In: Modern aspects of the use of interferons]. Moscow; 1990. p.24. Russian.
8. Filipova TO. [Farmacological activity and some mechanisms of action of novel synthetic immune modulators] [Dr. Sc. (Biol) Thesis Abstract]. Odesa: Mechnikov State University; 1996. 47 p. Russian.
9. Liakhov SA, Litvinova LA, Suveyzdis YI, Rybalko LI, Diadiun ST. [Interferon inducing properties of mono- and bis-acridines]. Khim Farm Zh. 2000;34(9):20-1. Russian. https://doi.org/10.1023/A:1005238207958
10. Degr? M, Gl?z ET. Interferon induction in human cell cultures by small molecular inducers (tilorone and acridines). Acta Pathol Microbiol Scand B. 1977 Jun;85(3):189-94. https://doi.org/10.1111/j.1699-0463.1977.tb01695.x
11. Tazulakhova EB, Sa?itkulov AM, Barinski? IF, Ershov FI. [Effect of low-molecular interferon inducers in experimental hepatitis in mice]. Vopr Virusol. 1988 Mar-Apr;33(2):179-81. Russian.
12. Gupta DK, Gieselmann V, Hasilik A, von Figura K. Tilorone acts as a lysosomotropic agent in fibroblasts. Hoppe Seylers Z Physiol
13. Ospel'nikova TP. [Interferon and immunity systems in inflammatory gynecologic diseases. Correction of impairments with interferon inducers] [Cand. Sc. (Med) Thesis Abstract]. Odesa: Filatov Eye Disease and Tissue Therapy Institute. 18 p. Russian.
14. Algarra I, Gonz?lez A, P?rez M, Gaforio JJ, Garrido F. Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Clin Exp Immunol.1996 Mar;103(3):499-505.
15. [Report on the investigation of the effect of amixin on hyman lymphocytes]. Institute of bioorganic chemistry]. Institute of Bioorganic Chemistry, Russian Academy of Medical Sciences and Institute of Gene Biology, Russian Academy of Sciences. Moscow; 2001. Russian.
16. Velychko LM. [Immune correction with a2binterferon: an optimization component of the treatment of patients with uveal melanoma] [Cand. Sc. (Med) Thesis Abstract]. Kyiv: Kavetsky Experimental Pathology, Oncology and Radiobiology Institute; 2000. 19 p. Ukrainian.
17. Vorontsova AL, Kudriavets IuI. [Interferon as an important optimization component of the treatment of patients with uveal melanoma]. Onkologiia. 2000 1-2(2):16-20. Russian.
18. Poliakova SI, Velychko LN. [Immune correction effect of amixin in patients receiving the complex modality treatment for lacrimal gland tumors]. Oftalmol Zh. 2009;4:50-3. Russian. https://doi.org/10.31288/oftalmolzh200945053
19. Gluzman DF, Skliarenko LM, Nadgornaia VA, Kriachok IA. [Diagnostic tumor immunohistochemistry]. Kyiv: Morion; 2003. p.6-15. Russian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Л. Н. Величко, В. В. Вит, А. П. Малецкий, А. В. Богданова
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
